Novo Nordisk rebrands to 'Novo' as stock struggles amid GLP-1 market competition

Novo Nordisk has rebranded as 'Novo' and introduced a new corporate culture framework, 'The Novo Way,' to better compete with Eli Lilly in the obesity drug market. CEO Mike Doustdar noted that the shift reflects the transition of obesity treatments into a consumer-driven market. Despite the strategic pivot, the company's stock has fallen approximately 15.8% year-to-date and remains down over 60% from its 2024 peak, with analysts remaining cautious about the impact of its oral Wegovy pill on a broader turnaround.